A pilot study of recombinant human thrombopoietin in enhancing hematopoietic stem cell homing and engraftment after transplantation

Status

Recruiting

Phases

Phase 2

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OIN-17010831

Enrollment

Unknown

Registered

2017-03-10

Start date

2014-03-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematologic diseases

Interventions

recombinant human TPO group:subcutaneously injection of recombinant human TPO

Control group:no injection with recombinant human TPO

Eligibility

Sex/Gender

All

Age

11 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1) Hematopoietic diseases:: acute myeloid leukemia, acute lymphoblastic leukemia, severe aplastic anemia, myelodysplastic syndrome; 2) Ages 11-55, males and females; 3) Complete remission before transplantation and without CNS or extramedullary infiltration; 4) Voluntary written informed consent; 5) No completely HLA-identical donors; 6) No sever function diseases in heart, brain, lung, liver or kidney or other organs. 7) Volunteers can be followed up for the treatment effect after transplantation.

Exclusion criteria

Exclusion criteria: 1) No voluntary written informed consent or relatives' informed consent; 2) Ages under 11, and above 55; 3) Uncomplete remission before transplantation, with CNS or extramedullary infiltration; 4) Severe function disorder in major organs, or with tumor or severe infection diseases; 5) Not suitable for Haplo-HSCT.

Design outcomes

Primary

Measure	Time frame
neutrophil engraftment;platelet engraftment;platelet Recovery;	—

Secondary

Measure	Time frame
aGVHD;	—

Countries

China

Contacts

Public ContactXuetao Pei

Academy of Military Medical Sciences

shirlylyh@126.com+86 010 66931947

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026